| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-12-01 | Xoma (USA - CA) Novo Nordisk (Denmark) | XMetA Program | diabetes | licensing |
Metabolic diseases | Licensing agreement |
| 2015-12-01 | Institut des Biomolécules Max Mousseron - IBMM (France) SATT AxLR (France) 4P Pharma (France) | EAPB02303 | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2015-12-01 | Promethera Biosciences (Belgium) | nomination |
Metabolic diseases - Genetic diseases - Liver diseases | Nomination | ||
| 2015-12-01 | Biophytis (France) | nomination |
Metabolic diseases - Neurodegenerative diseases - Ophtalmological diseases | Nomination | ||
| 2015-12-01 | Adaptimmune (UK) Universal Cells (USA - PA) | allogeneic T-cell therapies | collaboration licensing development |
Cancer - Oncology | Licensing agreement | |
| 2015-12-01 | Molmed (Italy) | facility located in Milan | validation of a production plant | Rare diseases - Genetic diseases | Validation of a production plant | |
| 2015-11-30 | Heptares Therapeutics (UK) Pfizer (USA - NY) | new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets | R&D |
R&D agreement | ||
| 2015-11-30 | Txcell (France) | nomination |
Autoimmune diseases - Inflammatory diseases | Nomination | ||
| 2015-11-30 | Ablynx (Belgium) | nomination |
Nomination | |||
| 2015-11-30 | Acadia Pharmaceuticals (USA - CA) | nomination |
CNS diseases - Neurological diseases - Neurodegenerative diseases | Nomination | ||
| 2015-11-29 | Cell Therapy Catapult (UK) Kanagawa Prefecture (Japan) | collaboration |
Regenerative Medicine | Collaboration agreement | ||
| 2015-11-27 | Macrocure (Israel) | nomination |
Cardiovascular diseases - Regenerative Medicine | Nomination | ||
| 2015-11-24 | Novozymes (Denmark) Paras Biopharmaceuticals (Finland) | improved version (biobettter) of teriparatide | osteoporosis | R&D |
Bone diseases | R&D agreement |
| 2015-11-23 | Flamel Technologies (France) | nomination |
Nomination | |||
| 2015-11-23 | Evgen Pharma (UK) Spanish National Research Council (CSIC) University of Seville (Spain) | new chemical entities based on the core structure of sulforaphane | licensing |
Neurological diseases - Cancer - Oncology - Cerebrovascular diseases | Licensing agreement | |
| 2015-11-20 | Galena Biopharma (USA - OR) undisclosed private company | Abstral® (fentanyl) Sublingual Tablets | inadequately controlled breakthrough cancer pain | product acquisition |
Cancer - Oncology | Product acquisition |
| 2015-11-19 | Ipsen (France) Interprotein Corporation (Japan) | endocrinological diseases such as Cushing\'s disease | R&D |
Endocrinological diseases - Hormonal diseases - Rare diseases | R&D agreement | |
| 2015-11-19 | Immune Pharmaceuticals (USA - MA, Israel) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-11-19 | AmpliPhi BioSciences (USA - VA) University of Adelaide (Australia) | AB-SA01 | chronic rhinosinusitis associated with Staphylococcus aureus infection | clinical research |
Infectious diseases | Clinical research agreement |
| 2015-11-19 | Aduro Biotech (USA - CA) | Aduro Biotech Europe | establishment of a new subsidiary in the EU |
Cancer - Oncology | Establishment of a new subsidiary in the EU |
